Lineage Cell Therapeutics (LCTX) Capital Expenditures Growth (5y) (2015 - 2026)
Lineage Cell Therapeutics (LCTX) Capital Expenditures Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Lineage Cell Therapeutics | 267.08 Mn | 203.18 Mn | 1.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.97% |
| Dec 31, 2025 | 83.33% |
| Sep 30, 2025 | -41.05% |
| Jun 30, 2025 | 18.47% |
| Mar 31, 2025 | 57.53% |
| Dec 31, 2024 | 139.71% |
| Sep 30, 2024 | -25.52% |
| Jun 30, 2024 | -23.83% |
| Mar 31, 2024 | -25.80% |
| Dec 31, 2023 | -27.68% |
| Sep 30, 2023 | -3.02% |
| Jun 30, 2023 | 49.47% |
| Mar 31, 2023 | -5.03% |
| Dec 31, 2022 | -24.68% |
| Sep 30, 2022 | -8.91% |
| Jun 30, 2022 | -17.83% |
| Mar 31, 2022 | -26.54% |
| Dec 31, 2021 | -40.57% |
| Jun 30, 2021 | 63.62% |
| Mar 31, 2021 | -47.16% |